Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of Leishmania (Viannia) braziliensis.
Carolina Cincurá, Clara Mônica F de Lima, Paulo R L Machado...
https://pubmed.ncbi.nlm.nih.gov/28722607/Actively Recruiting
Led by Fundacion Nacional de Dermatologia · Updated on 2025-02-26
30
Participants Needed
1
Research Sites
13 weeks
Total Duration
Researchers are evaluating the combination of inhaled pentamidine and oral miltefosine as a treatment for mucosal leishmaniasis caused by Leishmania braziliensis in Bolivia. Mucosal leishmaniasis is a severe form of the disease that damages the nose, throat, and related areas and is difficult to cure with traditional treatments. This phase 2 study aims to improve cure rates, especially for moderate to severe cases, by using a non-intravenous drug combination. Participants will receive oral miltefosine three times daily for 28 days and inhaled pentamidine at 300 mg on specific days 1, 3, 5, 8, 10, 12, 15, 17, 19, and 22. The study plans to enroll 20 patients with moderate to severe disease and up to 10 patients with milder cases. This combination therapy is fully non-parenteral and is expected to minimize overlapping side effects. During the study, researchers will monitor patients for effectiveness of the treatment over 25 months and track any treatment-emergent side effects for 6 months. Patients will undergo evaluations by ENT specialists and parasitological confirmation tests before enrollment. The study includes safety assessments such as blood tests, liver and kidney function monitoring, and heart evaluations. Participants will be followed throughout the treatment and for an extended period to assess cure and safety outcomes.
CONDITIONS
Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral Miltefosine
J
jaime soto, MD
P
Paula Soto, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fundacion Nacional de Dermatologia
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 28 days
Participants receive oral miltefosine capsules three times daily for 28 days combined with inhaled pentamidine administered on days 1, 3, 5, 8, 10, 12, 15, 17, 19, and 22.
10 inhalation visits and daily oral medication for 28 days
Duration - Up to 25 months
Participants are monitored for treatment efficacy and safety, including adverse events, for up to 25 months after treatment.
Visits scheduled during 6 months for adverse event monitoring and long-term follow-up visits up to 25 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Carolina Cincurá, Clara Mônica F de Lima, Paulo R L Machado...
https://pubmed.ncbi.nlm.nih.gov/28722607/J Soto, J Toledo, L Valda...
https://pubmed.ncbi.nlm.nih.gov/17205440/Matteo Piccica, Filippo Lagi, Alessandro Bartoloni...
https://pubmed.ncbi.nlm.nih.gov/33890115/Janaína de Pina Carvalho, Sarah Nascimento Silva, Mariana Lourenço Freire...
https://pubmed.ncbi.nlm.nih.gov/36395328/Naomi Aronson, Barbara L Herwaldt, Michael Libman...
https://pubmed.ncbi.nlm.nih.gov/27927991/Fundacion Nacional de Dermatologia
Lead Sponsor